Gonal-f Pen Injection - How to use!
Instructions for Injecting Gonal-f® RFF Redi-ject Pen Encompass Fertility Treatment
Consumer medicine information
What is in this leaflet
This leaflet answers some common questions about GONAL-f.
It does not contain all the available information.
It does not take the place of talking to your doctor, nurse or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you using GONAL-f against the benefits it is expected to have for you.
If you have any concerns about using this medicine, ask your doctor, nurse or pharmacist.
Keep this information with your medicine. You may need to read it again later.
GONAL-f contains follitropin alfa, which is similar to follicle stimulating hormone (FSH) found naturally in humans. GONAL-f belongs to a class of hormones called gonadotrophins.
FSH is necessary for
Growth and development of egg cells (follicles) in women
Sperm production in men.
GONAL-f can be used to bring about the development of follicles in women who are not ovulating and who have not responded to treatment with clomiphene citrate.
GONAL-f is also used to stimulate the development of several follicles in women undergoing assisted reproductive technologies (ART) such as in vitro fertilisation (IVF).
GONAL-f is used in combination with human chorionic gonadotrophin (hCG) to stimulate the production of sperm.
Ask your doctor if you have any questions about why GONAL-f has been prescribed for you. Your doctor may have prescribed it for another reason.
GONAL-f is available only on a doctor's prescription.
GONAL-f is not habit-forming.
When you must not use GONAL-f
Do not use GONAL-f if you have a history of allergy to any of the ingredients listed at the end of this leaflet.
Symptoms of an allergic reaction may include:
Do not use GONAL-f if you have tumours of the hypothalamus or pituitary gland.
Do not use GONAL-f if:
Do not use GONAL-f if:
you have increased levels of gonadotrophins indicating failure of the testes
your infertility is due to disorders other than hypogonadotrophic hypogonadism (low levels of gonadotrophins)
If you are not certain whether these conditions apply to you, or you are worried about anything on this list, tell your doctor.
Do not give this medicine to a child or elderly person.
Do not use this medicine after the expiry date (month/year) on the packaging has passed, or if the packaging is torn or shows signs of tampering. If your medicine has expired or is damaged, return it to your pharmacist / clinic for disposal.
If you are not sure whether you should start using GONAL-f, talk to your doctor.
Your doctor will assess you and your partner's fertility. This may include tests for other medical conditions, which may interfere with your ability to become pregnant. If necessary, other medical conditions may be treated before starting infertility treatments including GONAL-f.
Tell your doctor if you have any allergies to any foods, dyes, preservatives or any other medicines.
Tell your doctor if you have or have had any of the following medical conditions:
Your doctor will assess if you have any medical conditions which interfere with your ability to become pregnant.
Treatment with GONAL-f may increase your risk of developing a condition called ovarian hyperstimulation syndrome (OHSS). This is when the ovaries over-react to the hormonal treatment and become larger.
The most common symptom is lower abdominal pain. During stimulation your doctor will monitor your treatment by the use of ultrasound and/or blood tests to help determine if you are likely to develop OHSS. If necessary your doctor will delay or cancel your GONAL-f injection. You may also be advised to refrain from sexual intercourse until the end of the cycle if this occurs.
Compared to natural conception, the frequency of multiple pregnancies and births is higher in patients receiving treatments that stimulate follicle growth for ovulation induction. The majority of these are twins. Your doctor will monitor your response to treatment to minimise the chance of multiple pregnancies, because of the greater risks they carry for mothers and babies.
Compared to natural conception, the frequency of pregnancy loss is higher in patients undergoing treatments to stimulate follicle growth for ovulation induction.
There may be a slightly increased risk of birth defects in women using assisted reproductive technologies. This may be due to increased maternal age, genetic factors, multiple pregnancies or the procedures. An effect of medicines used to induce ovulation has not been excluded.
Tell your doctor if you or a family member have or have had signs of blood clots (e.g. pain, warmth, redness, numbness or tingling in the arm or leg). Treatment with GONAL-f and hCG may increase the risk of blood clots forming in your blood vessels.
Talk to your doctor about any concerns you may have before undergoing treatment or before you start using GONAL-f.
Elevated FSH blood levels are indicative of testicular failure. Your doctor may ask you for a semen analysis to assess your response to treatment.
Talk to your doctor about any concerns you may have before you start using GONAL-f
Tell your doctor if you are taking any other medicines, including:
Some medicines may be affected by GONAL-f or may affect how well it works.
Your doctor has more information on medicines to be careful with or avoid while using GONAL-f.
Follow all directions given to you by your doctor, nurse or pharmacist carefully. They may differ from the information contained in this leaflet.
Treatment with GONAL-f should be started under the supervision of a specialist doctor experienced in fertility treatment.
GONAL-f is given as a course of daily injections.
You should have your injection at the same time each day.
How much to inject
Your doctor will decide the correct dose of GONAL-f for you. Your dose of GONAL-f may be adjusted depending on your individual response to treatment. Please consult your doctor if you are in any doubt.
The following is a guide to the common dose.
Women who are not ovulating
The common dose usually starts at 75IU (5.46 microgram) daily. The dose may be adjusted as your treatment progresses. The maximal daily dose is usually not higher than 225 IU (16.5 microgram).
Women undergoing assisted reproductive technologies
The common dose usually starts at 150 IU (10.92 microgram) daily, commencing on day 2 or 3 of the cycle. The dose may be adjusted as your treatment progresses. The maximal daily dose is usually not higher than 450 IU (32.76 microgram).
Men with hypogonadotrophic hypogonadism
GONAL-f is commonly given with hCG. The common dose usually starts at 150 IU (10.92 microgram) three times a week.
How to inject
GONAL-f is given as a subcutaneous (under your skin) injection in the lower abdominal area or thigh.
GONAL-f is intended to be injected by you or your partner.
Alternatively your doctor or a nurse may give you these injections.
If your doctor or nurse decides you can give the injections yourself, the doctor or nurse will teach you the injection technique.
Do not self-inject until you are sure of how to do it.
Read the Instructions for Use provided in the pack carefully before commencing injections. Your partner may be trained to give the injection at home.
Where to inject
GONAL-f is usually given in the lower abdominal area (except around the navel and waistline) or the front of your thigh. The injection site should be changed daily to lessen possible injection site reactions.
Do not inject into any areas in which you feel lumps, firm knots, depressions, pain, or see any discolouration.
Talk to your doctor if you find anything unusual when injecting.
How long to use GONAL-f for
The length of treatment varies with each patient. It is possible to have more than one treatment cycle of GONAL-f.
The combination treatment of GONAL-f and hCG could continue for at least 4 months and may continue for up to 18-24 months.
If you forget to inject GONAL-f
If you forget an injection or are not sure what to do, contact your doctor or nurse immediately for advice.
Do not inject a double dose on any day.
Ask your doctor if you are not sure what to do or have trouble remembering to inject your medicine.
If you injected too much
Immediately contact your doctor or the Poisons Information Centre (In Australia telephone 131 126) if you are concerned that you have given yourself too much or someone else has injected themselves with GONAL-f.
Your doctor will carefully monitor your response to GONAL-f by using ultrasound, blood tests or semen analysis.
Things you must do
See your doctor regularly. Your doctor will monitor you closely throughout your treatment.
If you are about to be started on any new medicine, tell your doctor and pharmacist that you are using GONAL-f.
If you plan to have surgery, tell your doctor or dentist that you are using GONAL-f.
Tell all doctors, dentists and pharmacists who are treating you that you are using GONAL-f.
Tell your doctor immediately if you become pregnant while using GONAL-f.
Things you must not do
If you are self-injecting do not:
Things to be careful of
Be careful driving or operating machinery until you know how GONAL-f affects you.
Tell your doctor as soon as possible if you do not feel well while using GONAL-f. All medicines can have side effects. Sometimes they are serious, most of the time they are not.
Do not be alarmed by this list of possible side effects. You may not experience any of them.
Ask your doctor or pharmacist to answer any questions you may have.
If you get any side effects, do not stop using GONAL-f without first talking to your doctor.
Tell your doctor immediately, or go to Accident and Emergency at your nearest hospital if you notice any of the following:
signs of an allergic reaction, including swelling of the face, lips, tongue, or other parts of the body; shortness of breath, wheezing or difficulty breathing; severe skin rash, itching or hives.
Tell your doctor if you notice any of the following and they worry you:
pain, redness, itching or swelling at the site of injection during your treatment with GONAL-f
Ectopic pregnancy (embryo implanted outside the womb) may occur, especially in women with prior tubal disease.
Tell your doctor if you notice any of the following and they worry you:
These are common side effects.
Tell your doctor if you notice anything else that is making you feel unwell. Other side effects not listed above may also occur in some patients.
Prior to using, store GONAL-f PEN in the original package at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light.
Should refrigeration be unavailable, the GONAL-f PEN can be stored below 25°C for up to 3 months and away from light.
After first piercing the GONAL-f PEN with a needle, GONAL-f PEN may be stored below 25°C for a maximum of 21 days with the cap on, in order to protect the product from light.
Do not use GONAL-f PEN if the solution contains particles or is not clear.
Do not use the product after the expiry date printed on the label.
Do not use GONAL-f if you notice any visible signs of deterioration or damage to the container.
Do not use GONAL-f on anyone else.
It is for your use only.
Do not store it or any other medicine in the bathroom or near a sink.
Do not leave it in the car.
Keep this medicine where children cannot reach it. A locked cupboard at least one-and-a-half-metres above the ground is a good place to store medicines.
If you are self-injecting, you should discard all sharps into a disposal unit.
If you have any GONAL-f that has expired or is left over from your treatment refer this to your clinic.
What it looks like
GONAL-f PEN is available in three strengths of 300 IU (21.84 microgram), 450 IU (32.76 microgram) and 900 IU (65.52 microgram).
GONAL-f PEN is pre-filled with a clear, colourless solution of 0.5 mL (300 IU), 0.75 mL (450 IU) or 1.5 mL (900 IU).
Each cartridge contains the following ingredients:
300 IU (21.84 microgram), 450 IU (32.76 microgram) or 900 IU (65.52 microgram)
GONAL-f 300 IU/0.5 mL (21.84 microgram/0.5 mL) PEN is supplied in packs of:
1 cartridge pre-assembled in a disposable pen and 8 needles for administration.
GONAL-f 450 IU/0.75 mL (32.76 microgram/0.75 mL) PEN is supplied in packs of:
1 cartridge pre-assembled in a disposable pen and 12 needles for administration.
GONAL-f 900 IU/1.5 mL (65.52 microgram/1.5 mL) PEN is supplied in packs of:
1 cartridge pre-assembled in a disposable pen and 20 needles for administration.
GONAL-f PEN is supplied in Australia by:
Merck Serono Australia Pty Ltd. 3-4/25 Frenchs Forest Road East. Frenchs Forest NSW 2086
For enquiries call: 1800 633 463
GONAL-f® 300 IU/0.5 ml (22 micrograms/0.5 ml), 450 IU/0.75 ml (33 micrograms /0.75 ml), 900 IU/1.5 ml (66 micrograms/1.5 ml) solution for injection in a pre-filled pen.
Qualitative composition: Pre-filled pens containing follitropin alfa, recombinant human follicle stimulating hormone (r-hFSH) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
(1) Anovulation (including polycystic ovarian syndrome, PCOS) in adult women who have been unresponsive to treatment with clomiphene citrate.
(2) Stimulation of multifollicular development in adult women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer .
(3) In association with a luteinising hormone (LH) preparation for stimulation of follicular development in adult women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.
(4) Stimulation of spermatogenesis in adult men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotropin (hCG) therapy.
Dosage and administration:
Initiate under the supervision of a physician experienced in the treatment of fertility disorders. For subcutaneous injection.
Women with anovulation (including PCOS): Daily injections, starting by Day 7 of the cycle. Treatment should be tailored to the patient’s response. Treatment typically commences at 75-150 IU FSH daily and is increased preferably by 37.5 or 75 IU at 7 or preferably 14-day intervals if required. Maximum daily dose is usually not higher than 225 IU FSH. If a patient fails to respond after 4 weeks of treatment; that cycle should be abandoned and treatment recommended at a higher starting dose. When an optimal response is obtained, a single injection of 250 micrograms r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last GONAL-f® injection. The patient is recommended to have coitus on the day of, and day following, hCG administration. Alternatively intrauterine insemination (IUI) may be performed. If the response is excessive, treatment should be stopped and the hCG withheld (see precautions).
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive technologies: A commonly used regimen for superovulation involves the administration of 150-225 IU of GONAL-f® daily, commencing on day 2 or 3 of the cycle. Continue treatment until adequate follicular development has been achieved. Maximum daily dose is usually not higher than 450 IU daily. A single injection of 250 micrograms r-hCG or 5,000 IU up to 10,000 IU hCG is administered 24-48 hours after the last GONAL-f® injection to induce final follicular maturation. Down-regulation with a gonadotropin-releasing hormone (GnRH) agonist or antagonist is commonly used in order to suppress the endogenous LH surge and to control tonic levels of LH. GONAL-f® is started approximately 2 weeks after the start of agonist treatment, both being continued until adequate follicular development is achieved.
Women with anovulation resulting from severe LH and FSH deficiency: Treatment should be tailored according to response. Treatment may commence at 75 IU of lutropin alfa daily with 75 IU-150 IU FSH. If appropriate, the FSH dose should be adapted after 7-14 day intervals and by 37.5 IU-75 IU increments for up to 5 weeks. When an optimal response is obtained, a single injection of 250 micrograms rhCG or administer 5,000 IU to 10,000 IU hCG 24-48 hours after the last lutropin alfa and GONAL-f® injections.The patient is recommended to have coitus on the day of, and on the day following, Hcg administration. Alternatively, IUI may be performed. If the response is excessive, treatment should be stopped and the hCG withheld.
Men with hypogonadotrophic hypogonadism: 150 IU GONAL-f® should be given three times a week, concomitantly with hCG, for a minimum of 4 months. If after this period the patient has not responded, the combination treatment may be continued. Current clinical experience indicates that treatment for at least 18 months may be necessary to achieve spermatogenesis.
Hypersensitivity to active substance or to any of the excipients, tumours of the hypothalamus or pituitary gland.
In women, ovarian enlargement or cyst not due to polycystic ovarian syndrome, gynaecological haemorrhages of unknown aetiology, ovarian, uterine or mammary carcinoma or when an effective response cannot be obtained such as primary ovarian failure, malformations of sexual organs or fibroid tumours of the uterus incompatible with pregnancy.
In men, primary testicular insufficiency.
Treatment with GONAL-f® should be initiated under the supervision of a physician experienced in the treatment of infertility problems. Self-administration should only be performed by patients adequately trained and with access to expert advice.
The first injection should be performed under direct medical supervision.
Patients with porphyria or a family history of porphyria should be closely monitored during treatment with GONAL-f®.
Assess couple’s infertility and putative contraindications for pregnancy before starting treatment.
Monitor for ovarian enlargement or hyperstimulation. Excessive ovarian response to gonadotropin treatment can give rise to ovarian hyperstimulation syndrome (OHSS) with varying degrees of severity.
Risk factors for OHSS include PCOS, as well as high or rapidly rising serum oestradiol levels.
To minimise the risk of OHSS, adherence to recommended doses and administration schedule is important.
Monitoring with ultrasound scans as well as oestradiol measurements are also recommended.
There is evidence that hCG can trigger OHSS and that the syndrome may be more severe and more protracted if pregnancy occurs.
If OHSS occurs, withhold hCG and advise the patient to avoid coitus or use barrier methods of contraception for at least 4 days.
Very rarely, severe OHSS may be complicated by ovarian torsion, pulmonary embolism, ischaemic stroke and myocardial infarction.
Patients should be advised of the potential risk of multiple births before starting treatment.
Ectopic pregnancy is more common following ART and may occur in patients with prior tubal disease.
Pregnancy loss is higher than in the normal population.
Prevalence of congenital malformations may be slightly higher than after spontaneous conceptions.
In women with recent or ongoing thromboembolic disease or those with generally recognised risk factors for thromboembolic events, treatment with gonadotropins increases the risk.
There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not yet established whether or not treatment with gonadotropins increases the risk of these tumours in infertile women.
GONAL-f® should not be used during breastfeeding.
In men, semen analysis is recommended 4–6 months after the beginning of the treatment in assessing the response. GONAL-f® should not be used in men when an effective response cannot be obtained. Interactions: Concomitant use of GONAL-f® with other medicinal products used to stimulate ovulation (e.g. hCG, clomiphene citrate) may potentiate the follicular response, whereas concurrent use of a GnRH agonist or antagonist to induce pituitary desensitisation may increase the dose of GONAL-f® needed to elicit an adequate ovarian response.
+ Treatment in women:
Very common: Headache, ovarian cysts, injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).
Common: abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting, diarrhoea; mild or moderate OHSS (including associated symptomatology).
Uncommon: Severe OHSS (including associated symptomatology).
Rare: Complication of severe OHSS.
Very rare: Mild to severe hypersensitivity reactions including anaphylactic reactions and shock, thromboembolism (usually associated with severe OHSS), exacerbation or aggravation of asthma.
+ Treatment in men:
Very common: Injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection), weight gain.
Common: Acne, gynaecomastia, varicocele.
Very rare: Mild to severe hypersensitivity reactions including anaphylactic reactions and shock, exacerbation or aggravation of asthma.
© All Copyrights 2023 by Multitalentit.com